On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
sage-10k_20181231.htm
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
An Update On Sage Therapeutics (NASDAQ:SAGE) | Seeking Alpha
PDF) Sage Therapeutics-Sitting On The Brink Of CNS Breakthroughs
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage Therapeutics surges 70% after depression drug breakthrough
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
